Jamaica
· Delayed Price · Currency is JMD Elite Diagnostic Statistics
Total Valuation
Elite Diagnostic has a market cap or net worth of JMD 639.65 million. The enterprise value is 1.03 billion.
| Market Cap | 639.65M |
| Enterprise Value | 1.03B |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Elite Diagnostic has 353.40 million shares outstanding. The number of shares has increased by 13.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 353.40M |
| Shares Change (YoY) | +13.98% |
| Shares Change (QoQ) | +7.94% |
| Owned by Insiders (%) | 17.29% |
| Owned by Institutions (%) | 28.82% |
| Float | 182.10M |
Valuation Ratios
The trailing PE ratio is 34.08.
| PE Ratio | 34.08 |
| Forward PE | n/a |
| PS Ratio | 0.83 |
| PB Ratio | 1.38 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.74 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.72, with an EV/FCF ratio of 10.84.
| EV / Earnings | 50.98 |
| EV / Sales | 1.24 |
| EV / EBITDA | 4.72 |
| EV / EBIT | 12.05 |
| EV / FCF | 10.84 |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.87.
| Current Ratio | 0.83 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 2.00 |
| Debt / FCF | 4.59 |
| Interest Coverage | 1.90 |
Financial Efficiency
Return on equity (ROE) is 4.13% and return on invested capital (ROIC) is 5.50%.
| Return on Equity (ROE) | 4.13% |
| Return on Assets (ROA) | 5.05% |
| Return on Capital (ROIC) | 5.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.78 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +16.76% |
| 50-Day Moving Average | 2.06 |
| 200-Day Moving Average | 1.72 |
| Relative Strength Index (RSI) | 35.21 |
| Average Volume (20 Days) | 20,190 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Elite Diagnostic had revenue of JMD 827.93 million and earned 20.19 million in profits. Earnings per share was 0.05.
| Revenue | 827.93M |
| Gross Profit | 547.98M |
| Operating Income | 85.46M |
| Pretax Income | 23.39M |
| Net Income | 20.19M |
| EBITDA | 189.02M |
| EBIT | 85.46M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 45.88 million in cash and 435.70 million in debt, giving a net cash position of -389.83 million or -1.10 per share.
| Cash & Cash Equivalents | 45.88M |
| Total Debt | 435.70M |
| Net Cash | -389.83M |
| Net Cash Per Share | -1.10 |
| Equity (Book Value) | 499.54M |
| Book Value Per Share | 1.31 |
| Working Capital | -39.71M |
Cash Flow
In the last 12 months, operating cash flow was 160.08 million and capital expenditures -65.11 million, giving a free cash flow of 94.97 million.
| Operating Cash Flow | 160.08M |
| Capital Expenditures | -65.11M |
| Free Cash Flow | 94.97M |
| FCF Per Share | 0.27 |
Margins
Gross margin is 66.19%, with operating and profit margins of 10.32% and 2.44%.
| Gross Margin | 66.19% |
| Operating Margin | 10.32% |
| Pretax Margin | 2.82% |
| Profit Margin | 2.44% |
| EBITDA Margin | 22.83% |
| EBIT Margin | 10.32% |
| FCF Margin | 11.47% |
Dividends & Yields
Elite Diagnostic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.98% |
| Shareholder Yield | -13.98% |
| Earnings Yield | 2.93% |
| FCF Yield | 14.85% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |